Abstract is: Steven A. Rosenberg (born 2 August 1940) is an American cancer researcher and surgeon, chief of Surgery at the National Cancer Institute in Bethesda, Maryland and a Professor of Surgery at the Uniformed Services University of Health Sciences and the George Washington University School of Medicine and Health Sciences. He pioneered the development of immunotherapy that has resulted in the first effective immunotherapies and the development of gene therapy. He is the first researcher to successfully insert foreign genes into humans.
| human | Q5 |
| P2381 | Academic Tree ID | 6345 |
| P3280 | BAnQ authority ID | 0000359613 |
| P268 | Bibliothèque nationale de France ID | 12268111w |
| P8179 | Canadiana Name Authority ID | ncf10924921 |
| P9984 | CANTIC ID | 981058610895006706 |
| P11496 | CiNii Research ID | 1140000791782091008 |
| P2163 | FAST ID | 41645 |
| P646 | Freebase ID | /m/0gpjyc |
| P227 | GND ID | 1232760110 |
| P269 | IdRef ID | 031471501 |
| P213 | ISNI | 0000000083590026 |
| P11249 | KBR person ID | 14708700 |
| P409 | Libraries Australia ID | 35939695 |
| P244 | Library of Congress authority ID | n79097023 |
| P1284 | Munzinger person ID | 00000019902 |
| P271 | NACSIS-CAT author ID | DA00776150 |
| P4619 | National Library of Brazil ID | 000337149 |
| P8189 | National Library of Israel J9U ID | 987007456085805171 |
| P5034 | National Library of Korea ID | KAC201763705 |
| P7699 | National Library of Lithuania ID | LNB:CLCF;=r5 |
| P950 | National Library of Spain ID | XX861375 |
| P1006 | Nationale Thesaurus voor Auteursnamen ID | 068118414 |
| P349 | NDL Authority ID | 00474031 |
| P691 | NL CR AUT ID | nlk20040160833 |
| P1015 | NORAF ID | 90093352 |
| P1375 | NSK ID | 000307057 |
| P1207 | NUKAT ID | n02022629 |
| P496 | ORCID iD | 0000-0002-8939-8910 |
| P7293 | PLWABN ID | 9810636233905606 |
| P3368 | Prabook ID | 1872307 |
| P3065 | RERO ID (obsolete) | 02-A003760388 |
| P3987 | SHARE Catalogue author ID | 101390 |
| P11686 | University of Barcelona authority ID | 981058610895006706 |
| P214 | VIAF ID | 315224699 |
| P10832 | WorldCat Entities ID | E39PBJfRFYxH6yh6qxp3wFQTHC |
| P512 | academic degree | Doctor of Philosophy | Q752297 |
| P166 | award received | Keio Medical Science Prize | Q1324940 |
| William B. Coley Award | Q918979 | ||
| Karl Landsteiner Memorial Award | Q1732108 | ||
| Leopold Griffuel Prize | Q1879505 | ||
| Massry Prize | Q1907790 | ||
| Albany Medical Center Prize | Q2637278 | ||
| National Medal of Technology and Innovation | Q937629 | ||
| Clarivate Citation Laureates | Q7795894 | ||
| AACR Award for Lifetime Achievement in Cancer Research | Q52413759 | ||
| AACR-CRI Lloyd J. Old Award in Cancer Immunology | Q52413917 | ||
| Novartis Prize for Clinical Immunology | Q56289445 | ||
| Fellow of the AACR Academy | Q61636373 | ||
| P27 | country of citizenship | United States of America | Q30 |
| P1343 | described by source | Obálky knih | Q67311526 |
| Medvik | Q99413897 | ||
| P1889 | different from | Steven A. Rosenberg | Q63865665 |
| P69 | educated at | Harvard University | Q13371 |
| Johns Hopkins University | Q193727 | ||
| P108 | employer | National Cancer Institute | Q664846 |
| George Washington University | Q432637 | ||
| P734 | family name | Rosenberg | Q1159003 |
| Rosenberg | Q1159003 | ||
| Rosenberg | Q1159003 | ||
| P101 | field of work | oncology | Q162555 |
| P735 | given name | ??? | Q17501985 |
| ??? | Q17501985 | ||
| P1412 | languages spoken, written or signed | English | Q1860 |
| P1559 | name in native language | Steven Rosenberg | |
| P106 | occupation | surgeon | Q774306 |
| university teacher | Q1622272 | ||
| immunologist | Q12119633 | ||
| oncologist | Q16062369 | ||
| P21 | sex or gender | male | Q6581097 |
| Q39136403 | 'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations. |
| Q37614812 | 2D TCR-pMHC-CD8 kinetics determines T-cell responses in a self-antigen-specific TCR system. |
| Q28553703 | 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one |
| Q36943923 | A High-avidity WT1-reactive T-Cell Receptor Mediates Recognition of Peptide and Processed Antigen but not Naturally Occurring WT1-positive Tumor Cells |
| Q45892913 | A Phase I study of an HLA-DPB1*0401-restricted T cell receptor targeting MAGE-A3 for patients with metastatic cancers |
| Q90287047 | A Phase II Study of Tumor-infiltrating Lymphocyte Therapy for Human Papillomavirus-associated Epithelial Cancers |
| Q45863693 | A Pilot Trial of the Combination of Vemurafenib with Adoptive Cell Therapy in Patients with Metastatic Melanoma |
| Q56890830 | A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Effect of Nystatin on the Development of Oral Irritation in Patients Receiving High-Dose Intravenous Interleukin-2 |
| Q40451831 | A Rapid Cell Expansion Process for Production of Engineered Autologous CAR-T Cell Therapies. |
| Q39621147 | A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer. |
| Q39785306 | A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity |
| Q35632469 | A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas |
| Q33917519 | A highly recurrent RPS27 5'UTR mutation in melanoma |
| Q69896756 | A large scale method of separating multiple lymphokines secreted by the murine EL-4 thymoma |
| Q36365851 | A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes |
| Q68892301 | A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 |
| Q34729692 | A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer. |
| Q39018359 | A novel murine T-cell receptor targeting NY-ESO-1. |
| Q33342339 | A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma |
| Q36299662 | A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer |
| Q36509683 | A pilot study of antiangiogenic therapy with bevacizumab and thalidomide in patients with metastatic renal cell carcinoma |
| Q67980070 | A pilot study of the combination of interleukin-2-based immunotherapy and radiation therapy |
| Q35182795 | A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response |
| Q68815180 | A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone |
| Q36430749 | A prospective analysis of positron emission tomography and conventional imaging for detection of stage IV metastatic melanoma in patients undergoing metastasectomy |
| Q72248479 | A prospective randomized trial evaluating colloid versus crystalloid resuscitation in the treatment of the vascular leak syndrome associated with interleukin-2 therapy |
| Q73665603 | A prospective, randomized, double-blind, placebo-controlled trial evaluating the effect of nystatin on the development of oral irritation in patients receiving high-dose intravenous interleukin-2 |
| Q53905620 | A randomized double-blinded comparison of the antiemetic efficacy of ondansetron and droperidol in patients receiving high-dose interleukin-2. |
| Q36509678 | A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer |
| Q37358371 | A simple and effective method to generate lentiviral vectors for ex vivo gene delivery to mature human peripheral blood lymphocytes |
| Q51050000 | A simplified method for the clinical-scale generation of central memory-like CD8+ T cells after transduction with lentiviral vectors encoding antitumor antigen T-cell receptors. |
| Q34512762 | A summary of the results of a review of 405 patients with non-Hodgkin's lymphoma at Stanford University |
| Q40831581 | A tumor-infiltrating lymphocyte from a melanoma metastasis with decreased expression of melanoma differentiation antigens recognizes MAGE-12. |
| Q41295186 | Acquired erythropoietin responsiveness of interleukin-2-dependent T lymphocytes retrovirally transduced with genes encoding chimeric erythropoietin/interleukin-2 receptors |
| Q33831940 | Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells |
| Q37454925 | Acute and long-term effects on limb function of combined modality limb sparing therapy for extremity soft tissue sarcoma |
| Q33299427 | Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo |
| Q38576508 | Adoptive Cell Therapy--Tumor-Infiltrating Lymphocytes, T-Cell Receptors, and Chimeric Antigen Receptors. |
| Q37129943 | Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2. |
| Q24644442 | Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens |
| Q36283034 | Adoptive cell therapy for the treatment of patients with metastatic melanoma |
| Q37778694 | Adoptive cell therapy: genetic modification to redirect effector cell specificity. |
| Q34043643 | Adoptive cell transfer as personalized immunotherapy for human cancer |
| Q38146713 | Adoptive cell transfer for patients with metastatic melanoma: the potential and promise of cancer immunotherapy. |
| Q24548019 | Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma |
| Q24644774 | Adoptive cell transfer: a clinical path to effective cancer immunotherapy |
| Q24546258 | Adoptive immunotherapy for cancer: building on success |
| Q28262548 | Adoptive immunotherapy for cancer: harnessing the T cell response |
| Q68940777 | Adoptive immunotherapy of a newly induced sarcoma: immunologic characteristics of effector cells |
| Q43707846 | Adoptive immunotherapy of a syngeneic murine leukemia with a tumor-specific cytotoxic T cell clone and recombinant human interleukin 2: correlation with clonal IL 2 receptor expression |
| Q71002947 | Adoptive immunotherapy of established syngeneic solid tumors: role of T lymphoid subpopulations |
| Q69875757 | Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma |
| Q40893119 | Adoptive immunotherapy of renal cell carcinoma: studies from the Surgery Branch, National Cancer Institute |
| Q37002020 | Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers. |
| Q35269067 | Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression |
| Q34310912 | Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells |
| Q45812987 | Adoptive transfer of tumor infiltrating lymphocytes for metastatic cervical cancer |
| Q33261122 | Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion |
| Q35210008 | Adoptive-cell-transfer therapy for the treatment of patients with cancer |
| Q52082723 | Adoptively Transferred Tumor-Infiltrating Lymphocytes Can Cure Established Metastatic Tumor in Mice and Persist Long-Term In Vivo as Functional Memory T Lymphocytes |
| Q37389018 | Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. |
| Q45893625 | Adoptively transferred tumor-infiltrating T cells target somatic cancer mutations in a human papillomavirus+ cancer patient with complete tumor regression |
| Q35257907 | Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics. |
| Q35904666 | Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease |
| Q34657707 | Altered CD8(+) T-cell responses when immunizing with multiepitope peptide vaccines |
| Q41003839 | Alternating chemotherapy and irradiation in the treatment of advanced Hodgkin's disease |
| Q45875006 | An Efficient Single-Cell RNA-Seq Approach to Identify Neoantigen-Specific T Cell Receptors. |
| Q34192290 | An antigenic peptide produced by reverse splicing and double asparagine deamidation |
| Q44635436 | An improved method for growing murine tumor-infiltrating lymphocytes with in vivo antitumor activity |
| Q33501570 | An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer |
| Q70805193 | Analysis of cytokine secretion by melanoma-specific CD4+ T lymphocytes |
| Q41200467 | Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions. |
| Q34657684 | Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade |
| Q35012297 | Analysis of the disintegrin-metalloproteinases family reveals ADAM29 and ADAM7 are often mutated in melanoma |
| Q37356835 | Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma |
| Q27851483 | Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. |
| Q34031748 | Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer |
| Q68814698 | Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2 |
| Q93037188 | Antigen Experienced T Cells from Peripheral Blood Recognize p53 Neoantigens |
| Q41239385 | Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy. |
| Q36700826 | Antitumor effects in mice of the intravenous injection of attenuated Salmonella typhimurium |
| Q68805101 | Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types |
| Q54433454 | Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy. |
| Q34954883 | Assessment of ovarian function after preparative chemotherapy and total body radiation for adoptive cell therapy |
| Q49266293 | Audiovestibular dysfunction associated with adoptive cell immunotherapy for melanoma. |
| Q69636948 | Augmentation of antitumor efficacy by the combination of recombinant tumor necrosis factor and chemotherapeutic agents in vivo |
| Q35382043 | Augmented lymphocyte expansion from solid tumors with engineered cells for costimulatory enhancement |
| Q64105836 | Author Correction: Combined inhibition of MEK and nuclear ERK translocation has synergistic antitumor activity in melanoma cells |
| Q64112309 | Author Correction: RGS7 is recurrently mutated in melanoma and promotes migration and invasion of human cancer cells |
| Q34657638 | Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. |
| Q29620717 | B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells |
| Q92060568 | BRAF Inhibition: Bridge or Boost to T-cell Therapy? |
| Q36327125 | Bcl-2 overexpression enhances tumor-specific T-cell survival |
| Q34703616 | Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer |
| Q41683954 | Biological and antitumor effects of recombinant human macrophage colony-stimulating factor in mice |
| Q45858725 | Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase. |
| Q42649114 | CARs on track in the clinic |
| Q72668269 | CD4+ T-cells from mice immunized to syngeneic sarcomas recognize distinct, non-shared tumor antigens |
| Q34299986 | CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma |
| Q24540429 | CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. |
| Q68545128 | CEPP(B): an effective and well-tolerated regimen in poor-risk, aggressive non-Hodgkin's lymphoma |
| Q35871798 | CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma |
| Q35190928 | CTLA-4 dysregulation of self/tumor-reactive CD8+ T-cell function is CD4+ T-cell dependent. |
| Q73900121 | Calcium ionophore-treated peripheral blood monocytes and dendritic cells rapidly display characteristics of activated dendritic cells |
| Q81925442 | Cancer immunotherapy |
| Q57152489 | Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer |
| Q39733329 | Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes |
| Q24548229 | Cancer immunotherapy: moving beyond current vaccines |
| Q24676216 | Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes |
| Q24679736 | Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma |
| Q36637039 | Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy |
| Q24654976 | Cancer regression in patients after transfer of genetically engineered lymphocytes |
| Q37570109 | Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes |
| Q35573819 | Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma |
| Q68698359 | Cellular immunotherapy of cancer |
| Q67881119 | Cellular mechanisms of the antitumor activity of recombinant IL-6 in mice |
| Q24530100 | Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells |
| Q41766668 | Characterization of Lymphocytes Infiltrating Human Breast Cancer, Specific Immune Reactivity Detected by Measuring Cytokine Secretion |
| Q70387548 | Characterization of Postsplenectomy Bacteremia among Patients with and without Lymphoma |
| Q36372755 | Characterization of T-cell receptors directed against HLA-A*01-restricted and C*07-restricted epitopes of MAGE-A3 and MAGE-A12. |
| Q38854579 | Characterization of an Immunogenic Mutation in a Patient with Metastatic Triple-Negative Breast Cancer. |
| Q36326582 | Characterization of genetically modified T-cell receptors that recognize the CEA:691-699 peptide in the context of HLA-A2.1 on human colorectal cancer cells |
| Q41554132 | Characterization of human tumor cell lines transduced with the cDNA encoding either tumor necrosis factor alpha (TNF-a) or interleukin-2 (IL-2). |
| Q41369700 | Characterization of the functional specificity of a cloned T-cell receptor heterodimer recognizing the MART-1 melanoma antigen. |
| Q71728277 | Characterization of the lysis of fresh human solid tumors by autologous lymphocytes activated in vitro with phytohemagglutinin |
| Q40808854 | Chemotherapy of the non-Hodgkin's lymphomas: the Stanford experience |
| Q34041792 | Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor |
| Q36079820 | Circulating IL-15 exists as heterodimeric complex with soluble IL-15Rα in human and mouse serum |
| Q39534880 | Circulating Tumor DNA as an Early Indicator of Response to T-cell Transfer Immunotherapy in Metastatic Melanoma |
| Q36757025 | Clinical Scale Zinc Finger Nuclease-mediated Gene Editing of PD-1 in Tumor Infiltrating Lymphocytes for the Treatment of Metastatic Melanoma. |
| Q67674180 | Clinical and surgical (laparotomy) evaluation of patients with non-Hodgkin's lymphomas |
| Q36110862 | Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVE® bioreactor |
| Q55638863 | Clinical scale zinc finger nuclease (ZFN)-driven gene-editing of PD-1 in tumor infiltrating lymphocytes (TIL) for the potential treatment of metastatic melanoma. |
| Q36291092 | Clinical trials in the non-Hodgkin's lymphomata at Stanford University experimental design and preliminary results |
| Q68925034 | Clinical trials with IL-2 |
| Q36102927 | Clinical-scale lentiviral vector transduction of PBL for TCR gene therapy and potential for expression in less-differentiated cells |
| Q36984473 | Collapse of the tumor stroma is triggered by IL-12 induction of Fas. |
| Q53712809 | Combination chemotherapy and radiotherapy for Hodgkin's disease |
| Q69736492 | Combination cytokine immunotherapy with tumor necrosis factor alpha, interleukin 2, and alpha-interferon and its synergistic antitumor effects in mice |
| Q71659952 | Combination therapy with interferon-gamma and interleukin-2 for the treatment of metastatic melanoma |
| Q64122192 | Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma |
| Q68090211 | Combined effects of chemotherapy and interleukin 2 in the therapy of mice with advanced pulmonary tumors |
| Q47097618 | Combined inhibition of MEK and nuclear ERK translocation has synergistic antitumor activity in melanoma cells. |
| Q40808905 | Combined modality therapy in malignant lymphomas |
| Q39617663 | Combined modality therapy of Hodgkin's disease.A report on the stanford trials |
| Q42622588 | Common expression of melanoma tumor-associated antigens recognized by human tumor infiltrating lymphocytes: analysis by human lymphocyte antigen restriction |
| Q34420417 | Comparative exome sequencing of metastatic lesions provides insights into the mutational progression of melanoma |
| Q68906281 | Comparative studies of the long-term growth of lymphocytes from tumor infiltrates, tumor-draining lymph nodes, and peripheral blood by repeated in vitro stimulation with autologous tumor |
| Q73062516 | Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease |
| Q40280069 | Comparison of common gamma-chain cytokines, interleukin-2, interleukin-7, and interleukin-15 for the in vitro generation of human tumor-reactive T lymphocytes for adoptive cell transfer therapy |
| Q35563824 | Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. |
| Q71009588 | Computed tomography, lymphography, and staging laparotomy: correlations in initial staging of Hodgkin disease |
| Q34025234 | Considerations for the clinical application of chimeric antigen receptor T cells: observations from a recombinant DNA Advisory Committee Symposium held June 15, 2010 |
| Q37354362 | Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor |
| Q43161957 | Continuous intravenous administration of live genetically modified salmonella typhimurium in patients with metastatic melanoma |
| Q33499384 | Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma. |
| Q53545190 | Curative intravenous adoptive immunotherapy of Meth A murine sarcoma. A histologic and immunohistochemical assessment. |
| Q36328394 | Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy |
| Q67666264 | Cytokine regulation of tumor necrosis factor-alpha and -beta (lymphotoxin)-messenger RNA expression in human peripheral blood mononuclear cells |
| Q35839860 | Cytokine-independent growth and clonal expansion of a primary human CD8+ T-cell clone following retroviral transduction with the IL-15 gene |
| Q69178157 | Cytokines alter target cell susceptibility to lysis. II. Evaluation of tumor infiltrating lymphocytes |
| Q46618196 | Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing |
| Q56903260 | Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis |
| Q36299657 | Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer |
| Q69735294 | Decrease in interleukin 2-induced vascular leakage in the lungs of mice by administration of recombinant interleukin 1 alpha in vivo |
| Q102074966 | Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee |
| Q40627166 | Delata-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. A prospective, randomized evaluation |
| Q39502796 | Delayed reactions to contrast media after interleukin-2 immunotherapy |
| Q36380718 | Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases |
| Q35223241 | Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice |
| Q35135031 | Development of a T cell receptor targeting an HLA-A*0201 restricted epitope from the cancer-testis antigen SSX2 for adoptive immunotherapy of cancer |
| Q45238704 | Development of an automated closed system for generation of human lymphokine-activated killer (LAK) cells for use in adoptive immunotherapy |
| Q34678708 | Development of human anti-murine T-cell receptor antibodies in both responding and nonresponding patients enrolled in TCR gene therapy trials |
| Q72111537 | Development of long-term cell lines and lymphoid clones reactive against murine and human tumors: a new approach to the adoptive immunotherapy of cancer |
| Q69994353 | Differences in the effects of host suppression on the adoptive immunotherapy of subcutaneous and visceral tumors |
| Q35638553 | Different adjuvanticity of incomplete freund's adjuvant derived from beef or vegetable components in melanoma patients immunized with a peptide vaccine. |
| Q61692954 | Differential Anti-MART-1/MelanA CTL Activity in Peripheral Blood of HLA-A2 Melanoma Patients in Comparison to Healthy Donors |
| Q71699059 | Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence of in vivo priming by tumor cells |
| Q45907700 | Discovery and characterization of an immunogenic neoantigen in a patient with metastatic triple negative breast cancer. |
| Q43933734 | Disseminated human malignant melanoma in congenitally immune-deficient (bg/nu/xid) mice |
| Q45892785 | Diversity of mutated antigen recognition by tumor infiltrating lymphocytes from patients with metastatic melanoma |
| Q37390239 | Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation |
| Q40411216 | Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting. |
| Q41958978 | Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens |
| Q45893979 | Durable complete response in a patient with metastatic melanoma following adoptive transfer of autologous T cells recognizing 10 mutated tumor antigens. |
| Q24596055 | Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy |
| Q37618652 | EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. |
| Q68818529 | Effect of anti-B16 melanoma monoclonal antibody on established murine B16 melanoma liver metastases |
| Q43745067 | Effect of combined therapy with lymphokine-activated killer cells, interleukin 2 and specific monoclonal antibody on established B16 melanoma lung metastases. |
| Q68805123 | Effect of corticosteroid on the antitumor activity of lymphokine-activated killer cells and interleukin 2 in mice |
| Q40663693 | Effect of hydration on plasma-methotrexate levels |
| Q68805126 | Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice |
| Q36693023 | Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity |
| Q71566426 | Effects of high-dose methotrexate and vincristine on ovarian and testicular functions in patients undergoing postoperative adjuvant treatment of osteosarcoma |
| Q42066596 | Effects of murine tumor class I major histocompatibility complex expression on antitumor activity of tumor-infiltrating lymphocytes |
| Q71578923 | Effects of postoperative adjuvant chemotherapy and radiotherapy on ovarian function in women undergoing treatment for soft tissue sarcoma |
| Q44108177 | Efficacy of adjuvant radiation therapy in the treatment of soft tissue sarcoma of the extremity: 20-year follow-up of a randomized prospective trial |
| Q33851742 | Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions. |
| Q77929305 | Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity |
| Q68128494 | Endothelial activation during interleukin 2 immunotherapy. A possible mechanism for the vascular leak syndrome |
| Q55086081 | Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model. |
| Q34624124 | Engineering improved T cell receptors using an alanine-scan guided T cell display selection system |
| Q46143578 | Engineering the immune response to "self" for effective cancer immunotherapy |
| Q36286122 | Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. |
| Q36286127 | Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability |
| Q57029270 | Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy |
| Q92782148 | Enhanced efficacy and limited systemic cytokine exposure with membrane-anchored interleukin-12 T-cell therapy in murine tumor models |
| Q36215613 | Enhanced receptor expression and in vitro effector function of a murine-human hybrid MART-1-reactive T cell receptor following a rapid expansion |
| Q39704543 | Enrichment of CD8+ cells from melanoma tumor-infiltrating lymphocyte cultures reveals tumor reactivity for use in adoptive cell therapy. |
| Q34567635 | Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4 |
| Q34360292 | Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19 |
| Q50917597 | Eradication of a disseminated syngeneic mouse lymphoma by systemic adoptive transfer of immune lymphocytes and its dependence upon a host component(s). |
| Q40585962 | Evaluation of computed tomography in the detection of pulmonary metastases.A prospective study |
| Q36294815 | Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma |
| Q35982211 | Evaluation of γ-retroviral vectors that mediate the inducible expression of IL-12 for clinical application |
| Q72873162 | Evidence for an orderly progression in the spread of Hodgkin's disease |
| Q69873472 | Evidence that lymphokine-activated killer cells and natural killer cells are distinct based on an analysis of congenitally immunodeficient mice |
| Q92580838 | Exome Sequencing of ABCB5 Identifies Recurrent Melanoma Mutations that Result in Increased Proliferative and Invasive Capacities |
| Q35179796 | Exome sequencing identifies GRIN2A as frequently mutated in melanoma |
| Q36037070 | Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma. |
| Q73236549 | Expansion and characterization of T cells transduced with a chimeric receptor against ovarian cancer |
| Q44098509 | Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials |
| Q70278394 | Experimental and clinical studies with intraoperative radiotherapy |
| Q53182179 | Expression of MAGE-A and NY-ESO-1 in Primary and Metastatic Cancers. |
| Q37625469 | Expression of New York esophageal squamous cell carcinoma-1 in primary and metastatic melanoma. |
| Q36471604 | Expression of a "self-"antigen by human tumor cells enhances tumor antigen-specific CD4(+) T-cell function. |
| Q37113080 | Expression profiling of TCR-engineered T cells demonstrates overexpression of multiple inhibitory receptors in persisting lymphocytes |
| Q53735726 | Extended-field radiation therapy in Hodgkin's disease. A progress report. |
| Q72873174 | Extended-field radical radiotherapy in advanced Hodgkin's disease: short-term results of 2 randomized clinical trials |
| Q53816438 | Extralymphatic Hodgkin's disease. Prognosis and response to therapy. |
| Q36178641 | Extrathymic generation of tumor-specific T cells from genetically engineered human hematopoietic stem cells via Notch signaling |
| Q68895797 | Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2 |
| Q41980691 | Extremity soft tissue sarcomas: analysis of prognostic variables in 300 cases and evaluation of tumor necrosis as a factor in stratifying higher-grade sarcomas |
| Q34197717 | FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions |
| Q43458837 | Factors predicting survival in adults with stage I and II large-cell lymphoma treated with primary radiation therapy |
| Q70771870 | Female Reproductive Potential after Treatment for Hodgkin's Disease |
| Q36835348 | Frequency of MART-1/MelanA and gp100/PMel17-specific T cells in tumor metastases and cultured tumor-infiltrating lymphocytes |
| Q37309027 | Frequent mutations in the MITF pathway in melanoma |
| Q51084293 | Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens. |
| Q77436967 | Functional dissociation between local and systemic immune response during anti-melanoma peptide vaccination |
| Q36908627 | Functional heterogeneity of vaccine-induced CD8(+) T cells |
| Q37185223 | Gene expression profiling using nanostring digital RNA counting to identify potential target antigens for melanoma immunotherapy |
| Q34245416 | Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice |
| Q24623215 | Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen |
| Q34354588 | Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction |
| Q36327157 | Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes |
| Q70030313 | Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy |
| Q36924658 | Generation of NY-ESO-1-specific CD4+ and CD8+ T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design. |
| Q72111115 | Generation of long-term T-lymphoid cell lines with specific cytotoxic reactivity for a syngeneic murine lymphoma |
| Q71006725 | Generation of lytic and proliferative lymphoid clones to syngeneic tumor: in vitro and in vivo studies |
| Q36551911 | Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients |
| Q41380419 | Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines. Fine specificity and MART-1 melanoma antigen recognition. |
| Q35001971 | Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies. |
| Q46576306 | Genetic inference of immune responsiveness of melanoma cancer patients to TIL therapy |
| Q34703587 | Glucocorticoids do not inhibit antitumor activity of activated CD8+ T cells |
| Q44933177 | HLA association with response and toxicity in melanoma patients treated with interleukin 2-based immunotherapy |
| Q72185983 | Helper T cells infiltrating human renal cell carcinomas have the phenotype of activated memory-like T lymphocytes |
| Q33452632 | Hematologic effects of immunotherapy with lymphokine-activated killer cells and recombinant interleukin-2 in cancer patients. |
| Q67700700 | Hematologic neoplasia in patients treated for Hodgkin's disease |
| Q35613477 | Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells |
| Q54240398 | Hemodynamic effects of the administration of tumor-infiltrating lymphocytes to cancer patients. |
| Q44397830 | Heterogeneity of lymphokine-activated killer cells induced by IL-2. Separate lymphoid subpopulations lyse tumor, allogeneic blasts, and modified syngeneic blasts |
| Q40978441 | High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. |
| Q36471584 | High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens |
| Q45893237 | High frequency CD8+PD-1+ TCR clonotypes isolated from fresh melanomas display anti-tumor activity |
| Q33303162 | High-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumor cell lines. |
| Q95932162 | High-affinity oligoclonal TCRs define effective adoptive T cell therapy targeting mutant KRAS-G12D |
| Q36363721 | High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. |
| Q43518310 | High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial |
| Q34657652 | High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation |
| Q46507832 | Highlights of the society for immunotherapy of cancer (SITC) 27th annual meeting |
| Q41613178 | Hodgkin's disease, stages I and II occurring below the diaphragm |
| Q35789284 | Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene |
| Q34557953 | Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. |
| Q46204344 | Human lymphokine-activated killer cells: further isolation and characterization of the precursor and effector cell |
| Q41018130 | Human melanoma antigens recognized by T lymphocytes |
| Q33624972 | Human melanoma metastases demonstrate nonstochastic site-specific antigen heterogeneity that correlates with T-cell infiltration |
| Q69613975 | Human tumor infiltrating lymphocytes. Analysis of lymphokine mRNA expression and relevance to cancer immunotherapy |
| Q36908547 | Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules |
| Q34330224 | IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain |
| Q35578622 | IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. |
| Q24621753 | IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells |
| Q34657691 | IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients |
| Q36327148 | IL-2 and IL-15 each mediate de novo induction of FOXP3 expression in human tumor antigen-specific CD8 T cells |
| Q36677310 | IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy |
| Q68456823 | IL-2-based immunotherapy alters circulating neutrophil Fc receptor expression and chemotaxis |
| Q41841133 | IL-4 regulates IL-2 induction of lymphokine-activated killer activity from human lymphocytes |
| Q69735138 | IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors |
| Q69735865 | IL-6/IFN-beta-2 as a circulating hormone. Induction by cytokine administration in humans |
| Q24546362 | IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells |
| Q39664105 | Identification and characterization of a tumor infiltrating CD56(+)/CD16 (-) NK cell subset with specificity for pancreatic and prostate cancer cell lines. |
| Q36908561 | Identification of BING-4 cancer antigen translated from an alternative open reading frame of a gene in the extended MHC class II region using lymphocytes from a patient with a durable complete regression following immunotherapy |
| Q42674567 | Identification of MART-1-specific T-cell receptors: T cells utilizing distinct T-cell receptor variable and joining regions recognize the same tumor epitope |
| Q91623677 | Identification of Neoantigen-Reactive Tumor-Infiltrating Lymphocytes in Primary Bladder Cancer |
| Q24649346 | Identification of a colorectal tumor-associated antigen (COA-1) recognized by CD4(+) T lymphocytes |
| Q36364355 | Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes |
| Q42651562 | Identification of a new shared HLA-A2.1 restricted epitope from the melanoma antigen tyrosinase |
| Q77536089 | Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2) |
| Q41321782 | Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes. |
| Q70341820 | Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2 |
| Q36713763 | Identification of endogenous HLA-A2-restricted reactivity against shared melanoma antigens in patients using the quantitative real-time polymerase chain reaction |
| Q36509702 | Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression |
| Q45893772 | Identification of mutation-specific tumor infiltrating lymphocytes from metastatic ovarian cancer |
| Q44999145 | Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. |
| Q36363449 | Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes |
| Q41099384 | Identification of tumor-regression antigens in melanoma. |
| Q36376523 | Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma |
| Q41825723 | Identification of unique murine tumor associated antigens by tumor infiltrating lymphocytes using tumor specific secretion of interferon-gamma and tumor necrosis factor |
| Q98614792 | Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors |
| Q57118558 | Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer |
| Q36907938 | Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia |
| Q71614134 | Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides |
| Q36430745 | Immunization of HLA-A*0201 and/or HLA-DPbeta1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen |
| Q77552569 | Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay |
| Q35190921 | Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens |
| Q36642248 | Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase |
| Q38823554 | Immunogenicity of somatic mutations in human gastrointestinal cancers. |
| Q69383998 | Immunohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans |
| Q72991676 | Immunohistologic responses within dermal metastatic melanoma lesions of patients treated with a synthetic peptide vaccine |
| Q91311678 | Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer |
| Q89722643 | Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma |
| Q41732697 | Immunoselection of a human melanoma resistant to specific lysis by autologous tumor-infiltrating lymphocytes. Possible mechanisms for immunotherapeutic failures |
| Q34219970 | Immunotherapy for metastatic solid cancers |
| Q69906777 | Immunotherapy of cancer with lymphokine-activated killer cells and recombinant interleukin-2 |
| Q68796572 | Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2 |
| Q48036736 | Immunotherapy: The path to win the war on cancer? |
| Q96639706 | Impact of Cysteine Residues on MHC Binding Predictions and Recognition by Tumor-Reactive T Cells |
| Q84559560 | Impact of a recombinant fowlpox vaccine on the efficacy of adoptive cell therapy with tumor infiltrating lymphocytes in a patient with metastatic melanoma |
| Q67315674 | Impact of salvage treatment on initial relapses in patients with Hodgkin disease, stages I-III |
| Q45767602 | Improved gene transfer into human lymphocytes using retroviruses with the gibbon ape leukemia virus envelope |
| Q71527769 | Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues |
| Q34757266 | Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment |
| Q72858702 | In search of an effective antiemetic: a nusring staff participates in marijuana research |
| Q41719598 | In vitro and in vivo antitumor properties of a T-cell clone generated from murine tumor-infiltrating lymphocytes |
| Q70327210 | In vitro differentiation of T-cells capable of mediating the regression of established syngeneic tumors in mice |
| Q72133294 | In vitro growth of cytotoxic human lymphocytes. II. Use of T cell growth factor (TCGF) to clone human T cells |
| Q70545916 | In vitro growth of cytotoxic human lymphocytes. III. The preparation of lectin-free T cell growth factor (TCGF) and an analysis of its activity |
| Q53576503 | In vitro growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors. |
| Q70161150 | In vitro growth of murine T cells. VI. Accelerated skin graft rejection caused by adoptively transferred cells expanded in T cell growth factor |
| Q43774102 | In vitro sensitization and expansion with viable tumor cells and interleukin 2 in the generation of specific therapeutic effector cells |
| Q68888616 | In vivo administration of interferon alpha and interleukin 2 induces proliferation of lymphoid cells in the organs of mice |
| Q43603587 | In vivo administration of purified Jurkat-derived interleukin 2 in mice |
| Q40821886 | In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2. |
| Q40815147 | In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. |
| Q70169536 | In vivo administration of purified human interleukin-2 to patients with cancer: development of interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors following interleukin-2 administration |
| Q68017292 | In vivo administration of recombinant macrophage colony-stimulating factor induces macrophage-mediated antibody-dependent cytotoxicity of tumor cells |
| Q71887324 | In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes |
| Q44233004 | In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2. |
| Q69205653 | In vivo induction of IL-6 by administration of exogenous cytokines and detection of de novo serum levels of IL-6 in tumor-bearing mice |
| Q70176041 | In vivo proliferation of adoptively transferred tumor-infiltrating lymphocytes in mice |
| Q34943798 | Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma |
| Q36144729 | Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. |
| Q33282703 | Inability to mediate prolonged reduction of regulatory T Cells after transfer of autologous CD25-depleted PBMC and interleukin-2 after lymphodepleting chemotherapy |
| Q35594089 | Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go? |
| Q35638571 | Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells |
| Q73202067 | Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression |
| Q59400469 | Individual cultures of melanoma tumor infiltrating lymphocytes possess distinct patterns of reactivity with mutated antigens identified by whole exome sequencing of autologous tumors |
| Q36509692 | Induction of CD4+ Th1 lymphocytes that recognize known and novel class II MHC restricted epitopes from the melanoma antigen gp100 by stimulation with recombinant protein |
| Q43560580 | Induction of antibody-dependent cellular cytotoxicity in vivo by IFN-alpha and its antitumor efficacy against established B16 melanoma liver metastases when combined with specific anti-B16 monoclonal antibody |
| Q45040842 | Induction of endogenous cytokine-mRNA in circulating peripheral blood mononuclear cells by IL-2 administration to cancer patients. |
| Q72989651 | Induction of melanoma reactive T cells by stimulator cells expressing melanoma epitope-major histocompatibility complex class I fusion proteins |
| Q44700343 | Initial relapse in previously treated Hodgkin's disease—II retrograde transdiaphragmatic extension |
| Q43712789 | Initial relapses in previously treated Hodgkin's disease. I. Results of second treatment |
| Q39650015 | Intercurrent death after Hodgkin disease therapy in radiotherapy and adjuvant MOPP trials |
| Q68099918 | Interleukin 2 and psoriasis |
| Q68090217 | Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity |
| Q36355725 | Interleukin 4 promotes the growth of tumor-infiltrating lymphocytes cytotoxic for human autologous melanoma |
| Q77914278 | Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place |
| Q41392239 | Interleukin-2-transduced lymphocytes grow in an autocrine fashion and remain responsive to antigen. |
| Q36327129 | Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes |
| Q36259372 | Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma |
| Q40803152 | Intraperitoneal administration of interleukin-2 in patients with cancer |
| Q55485579 | Intratumoral LAK cell and interleukin-2 therapy of human gliomas. |
| Q34827147 | In vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cells. |
| Q34720087 | Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis |
| Q34982519 | Irradiation enhances human T-cell function by upregulating CD70 expression on antigen-presenting cells in vitro |
| Q37100031 | Isolation and Characterization of an HLA-DPB1*04: 01-restricted MAGE-A3 T-Cell Receptor for Cancer Immunotherapy |
| Q45797575 | Isolation of T cell receptors specifically reactive with mutated tumor associated antigens |
| Q38797183 | Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression. |
| Q36165605 | Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes |
| Q38714331 | LIGHT Elevation Enhances Immune Eradication of Colon Cancer Metastases |
| Q74130857 | Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma |
| Q37373008 | Lack of specific gamma-retroviral vector long terminal repeat promoter silencing in patients receiving genetically engineered lymphocytes and activation upon lymphocyte restimulation |
| Q40242985 | Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer |
| Q44715013 | Large scale production of human lymphokine activated killer cells for use in adoptive immunotherapy |
| Q34657644 | Large-scale depletion of CD25+ regulatory T cells from patient leukapheresis samples |
| Q33688441 | Lentiviral vector design for optimal T cell receptor gene expression in the transduction of peripheral blood lymphocytes and tumor-infiltrating lymphocytes |
| Q36057563 | Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer. |
| Q39779492 | Limb-sparing surgery for soft tissue sarcomas: wound related morbidity in patients undergoing wide local excision. |
| Q45888653 | Liver resection for metastatic melanoma with postoperative tumor-infiltrating lymphocyte therapy. |
| Q50061565 | Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice. |
| Q40095482 | Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy |
| Q100457008 | Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy |
| Q40785085 | Long-term outcome in 87 patients with low-grade soft-tissue sarcoma |
| Q44681853 | Long-term survival of adoptively transferred tumor-infiltrating lymphocytes in mice. |
| Q37129939 | Loss of S100 antigenicity in metastatic melanoma |
| Q72085643 | Lymphoblastic lymphoma in adults: results of a pilot protocol |
| Q70090680 | Lymphokine-activated killer (LAK) cell phenomenon. IV. Lysis by LAK cell clones of fresh human tumor cells from autologous and multiple allogeneic tumors |
| Q45111534 | Lymphokine-activated killer (LAK) cells. Analysis of factors relevant to the immunotherapy of human cancer |
| Q54474925 | Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2. |
| Q50034163 | Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels. |
| Q72098225 | Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor |
| Q70282589 | Lysis of fresh human solid tumors by autologous lymphocytes activated in vitro with lectins |
| Q54486584 | Lysis of fresh natural killer-resistant tumor cells by lectin-activated syngeneic and allogeneic murine splenocytes. |
| Q70663523 | Lysis of human solid tumors by autologous cells sensitized in vitro to alloantigens |
| Q36361920 | Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain |
| Q36796813 | MAGE-A is More Highly Expressed Than NY-ESO-1 in a Systematic Immunohistochemical Analysis of 3668 Cases |
| Q73336748 | MHC class I-restricted recognition of a melanoma antigen by a human CD4+ tumor infiltrating lymphocyte |
| Q34050163 | MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, in vitro |
| Q53735871 | MOPP chemotherapy for advanced Hodgkin's disease. Prognostic factors in 81 patients. |
| Q68786760 | Manipulation of oxygen radical-scavenging capacity in mice alters host sensitivity to tumor necrosis factor toxicity but does not interfere with its antitumor efficacy |
| Q36286117 | Measuring tissue-based biomarkers by immunochromatography coupled with reverse-phase lysate microarray |
| Q70502480 | Mechanism of action of Cyclosporin A: inhibition of lymphokine secretion studied with antigen-stimulated T cell hybridomas |
| Q37930429 | Mechanisms of immunologic antitumor therapy: lessons from the laboratory and clinical applications |
| Q39671316 | Mechanistic aspects of successful immunotherapy of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin-2. |
| Q41483867 | Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes |
| Q46577867 | Melanoma-associated B cells are distinct from peripheral blood-derived B cells, and may serve as a source of tumor-targeting antibodies |
| Q36366680 | Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes |
| Q64990433 | Melanoma: Why is sentinel lymph node biopsy 'standard of care' for melanoma? |
| Q36430680 | Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy |
| Q61124550 | Memory T cells targeting oncogenic mutations detected in peripheral blood of epithelial cancer patients |
| Q45048055 | Metabolic and renal effects of interleukin-2 immunotherapy for metastatic cancer. |
| Q37528784 | Metastasectomy Following Immunotherapy with Adoptive Cell Transfer for Patients with Advanced Melanoma. |
| Q93817055 | Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8 T cells via TLR4 signaling |
| Q35901034 | Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. |
| Q34823783 | Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy |
| Q36127769 | Minimally invasive liver resection to obtain tumor-infiltrating lymphocytes for adoptive cell therapy in patients with metastatic melanoma |
| Q30621114 | Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells |
| Q36908551 | Mobilization of dendritic cell precursors in patients with cancer by flt3 ligand allows the generation of higher yields of cultured dendritic cells |
| Q50925934 | Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktails. |
| Q34936175 | Modulation by IL-2 of CD70 and CD27 expression on CD8+ T cells: importance for the therapeutic effectiveness of cell transfer immunotherapy |
| Q70404768 | Modulation of murine tumor major histocompatibility antigens by cytokines in vivo and in vitro |
| Q36696205 | Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma |
| Q34139613 | Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells. |
| Q47872727 | Murine Autoantibodies to a Cryptic Membrane Antigen: Possible Explanation for Neuraminidase-Induced Increase in Cell Immunogenicity2 |
| Q46075479 | Murine lymphokine-activated killer (LAK) cells: phenotypic characterization of the precursor and effector cells |
| Q34729631 | Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regression. |
| Q35382936 | Mutational and functional analysis of the tumor-suppressor PTPRD in human melanoma |
| Q34682013 | Mutational and functional analysis reveals ADAMTS18 metalloproteinase as a novel driver in melanoma |
| Q37385138 | Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma |
| Q36029045 | Mutational inactivation of STAG2 causes aneuploidy in human cancer |
| Q34388520 | Mutational signatures of de-differentiation in functional non-coding regions of melanoma genomes |
| Q55056515 | Myeloid cells obtained from the blood but not from the tumor can suppress T-cell proliferation in patients with melanoma. |
| Q39641278 | NIH conference. New approaches to the immunotherapy of cancer using interleukin-2. |
| Q64958969 | NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis. |
| Q64898281 | NY-ESO-1 may be a potential target for lung cancer immunotherapy. |
| Q91328734 | Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers |
| Q35996395 | New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer |
| Q41002229 | No Initial Therapy for Stage III and IV Non-Hodgkin's Lymphomas of Favorable Histologic Types |
| Q56899941 | No correlation between clinical response to CTLA-4 blockade and presence of NY-ESO-1 antibody in patients with metastatic melanoma |
| Q54113062 | Non-Hodgkin's lymphomas. 3. Preliminary results of radiotherapy and a proposal for new clinical trials. |
| Q54576741 | Non-Hodgkin's lymphomas. IV. Clinicopathologic correlation in 405 cases. |
| Q44971100 | Non-Hodgkin's lymphomas.V. Results of radiotherapy |
| Q24648492 | Normal tissue depresses while tumor tissue enhances human T cell responses in vivo to a novel self/tumor melanoma antigen, OA1 |
| Q35745453 | Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity |
| Q34581746 | Novel somatic mutations in heterotrimeric G proteins in melanoma |
| Q34194434 | Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer |
| Q40983022 | Occurrence of Non-Hodgkin's Lymphoma after Therapy for Hodgkin's Disease |
| Q37275309 | Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma |
| Q88407814 | Outcomes of Adoptive Cell Transfer With Tumor-infiltrating Lymphocytes for Metastatic Melanoma Patients With and Without Brain Metastases |
| Q38734913 | Overview of interleukin-2 as an immunotherapeutic agent |
| Q37726682 | PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors |
| Q33940443 | Pancreatic cancer: Hurdles in the engineering of CAR-based immunotherapies |
| Q36311681 | Paraneoplastic granulocytosis in metastatic melanoma |
| Q35063407 | Parathyroid hormone-related protein and hypercalcemia in patients with metastatic melanoma: case report and review |
| Q36344582 | Partial reduction of human FOXP3+ CD4 T cells in vivo after CD25-directed recombinant immunotoxin administration |
| Q43500461 | Pathologic findings associated with interleukin-2-based immunotherapy for cancer: a postmortem study of 19 patients |
| Q41734221 | Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy |
| Q52491491 | Penetration of recombinant interleukin-2 across the blood-cerebrospinal fluid barrier. |
| Q35044333 | Persistence of CTL clones targeting melanocyte differentiation antigens was insufficient to mediate significant melanoma regression in humans |
| Q33210267 | Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy |
| Q35568556 | Personalized cell transfer immunotherapy for B-cell malignancies and solid cancers |
| Q45896373 | Personalized immunotherapy for non-small cell lung cancer through identification of tumor-specific mutations by next generation sequencing and adoptive transfer of tumor infiltrating lymphocytes that recognize neoantigens |
| Q40865041 | Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100. |
| Q56899396 | Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma |
| Q72718104 | Phase I study of human leukocyte interferon in patients with advanced cancer |
| Q33340438 | Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma |
| Q37107516 | Phenotype and function of T cells infiltrating visceral metastases from gastrointestinal cancers and melanoma: implications for adoptive cell transfer therapy |
| Q34648472 | Phenotypic and functional maturation of tumor antigen-reactive CD8+ T lymphocytes in patients undergoing multiple course peptide vaccination |
| Q44710348 | Phenotypic characterization of murine tumor-infiltrating T lymphocytes |
| Q92436994 | Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor-transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma |
| Q55154464 | Prednisone in MOPP chemotherapy for Hodgkin's disease |
| Q58714103 | Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL |
| Q36327106 | Presentation of tumor antigens by dendritic cells genetically modified with viral and nonviral vectors |
| Q84600405 | Prevention of interleukin-2 withdrawal-induced apoptosis in lymphocytes retrovirally cotransduced with genes encoding an antitumor T-cell receptor and an antiapoptotic protein |
| Q34657676 | Primary human T lymphocytes engineered with a codon-optimized IL-15 gene resist cytokine withdrawal-induced apoptosis and persist long-term in the absence of exogenous cytokine |
| Q36327142 | Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines |
| Q50510003 | Production of recombinant MART-1 proteins and specific antiMART-1 polyclonal and monoclonal antibodies: use in the characterization of the human melanoma antigen MART-1. |
| Q70333123 | Prognostic factors in pathologic stage III Hodgkin's disease |
| Q36286133 | Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade |
| Q42259606 | Prospective evaluation of doxorubicin-induced cardiomyopathy resulting from postsurgical adjuvant treatment of patients with soft tissue sarcomas |
| Q38792012 | Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients |
| Q36456711 | Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. |
| Q42223110 | Prospective study of cardiomyopathy induced by adjuvant doxorubicin therapy in patients with soft-tissue sarcomas |
| Q34507561 | Prospects for gene-engineered T cell immunotherapy for solid cancers. |
| Q41619271 | Quality of life assessment of patients in extremity sarcoma clinical trials. |
| Q40964694 | Quantitation of T-cell receptor frequencies by competitive PCR: generation and evaluation of novel TCR subfamily and clone specific competitors |
| Q41174063 | RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: role of immune cell subpopulations |
| Q48251012 | RGS7 is recurrently mutated in melanoma and promotes migration and invasion of human cancer cells |
| Q37065838 | Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. |
| Q34536176 | Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer |
| Q36027584 | Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma |
| Q100758899 | Rapid Identification and Evaluation of Neoantigen-reactive T-Cell Receptors From Single Cells |
| Q34519488 | Rapid production of clinical-grade gammaretroviral vectors in expanded surface roller bottles using a "modified" step-filtration process for clearance of packaging cells |
| Q37197945 | Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression |
| Q74463509 | Recognition of an antigenic peptide derived from tyrosinase-related protein-2 by CTL in the context of HLA-A31 and -A33 |
| Q34657661 | Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR. |
| Q36321176 | Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma |
| Q90688967 | Recognition of human gastrointestinal cancer neoantigens by circulating PD-1+ lymphocytes |
| Q71804817 | Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides |
| Q72133139 | Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression |
| Q35535509 | Recognition of shared melanoma antigens by human tumor-infiltrating lymphocytes |
| Q73475194 | Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma |
| Q36752428 | Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy |
| Q36484723 | Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma |
| Q69909342 | Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells |
| Q37112088 | Recurrent inactivating RASA2 mutations in melanoma |
| Q33418729 | Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer |
| Q67856845 | Relapse after response to interleukin-2-based immunotherapy: patterns of progression and response to retreatment |
| Q33927506 | Relationship of p53 overexpression on cancers and recognition by anti-p53 T cell receptor-transduced T cells |
| Q24540135 | Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells |
| Q35749986 | Replication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements? |
| Q45790670 | Results of clinical trials with the administration of interleukin 2 and adoptive immunotherapy with activated cells in patients with cancer |
| Q43963971 | Retroviral transduction of human dendritic cells with a tumor-associated antigen gene. |
| Q36294795 | Risk of bowel perforation in patients receiving interleukin-2 after therapy with anti-CTLA 4 monoclonal antibody |
| Q68251706 | Risk of second cancers after treatment for Hodgkin's disease |
| Q37683228 | Routine Computer Tomography Imaging for the Detection of Recurrences in High-Risk Melanoma Patients |
| Q34582536 | Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases |
| Q34307987 | Selection of CD8+PD-1+ lymphocytes in fresh human melanomas enriches for tumor-reactive T cells |
| Q45785742 | Selection of circulating PD-1+ lymphocytes from cancer patients enriches for tumor-reactive and mutation-specific lymphocytes. |
| Q34657700 | Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2. |
| Q36327137 | Selective growth, in vitro and in vivo, of individual T cell clones from tumor-infiltrating lymphocytes obtained from patients with melanoma |
| Q54401823 | Separation and functional studies of the human lymphokine-activated killer cell. |
| Q68163347 | Separation and growth of human CD4+ and CD8+ tumor-infiltrating lymphocytes and peripheral blood mononuclear cells by direct positive panning on covalently attached monoclonal antibody-coated flasks |
| Q40641929 | Serum interleukin-6 levels in metastatic renal cell carcinoma before treatment with interleukin-2 correlates with paraneoplastic syndromes but not patient survival |
| Q54649386 | Shared human melanoma antigens. Recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas. |
| Q35860034 | Simplified method of the growth of human tumor infiltrating lymphocytes in gas-permeable flasks to numbers needed for patient treatment |
| Q36938866 | Simultaneous targeting of tumor antigens and the tumor vasculature using T lymphocyte transfer synergize to induce regression of established tumors in mice. |
| Q36713758 | Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions |
| Q93104450 | Single-Cell Transcriptome Analysis Reveals Gene Signatures Associated with T-cell Persistence Following Adoptive Cell Therapy |
| Q37236693 | Single-pass, closed-system rapid expansion of lymphocyte cultures for adoptive cell therapy |
| Q56902369 | Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent |
| Q70580238 | Soft tissue sarcoma: functional outcome after wide local excision and radiation therapy |
| Q34051230 | Somatic mutation of GRIN2A in malignant melanoma results in loss of tumor suppressor activity via aberrant NMDAR complex formation |
| Q28397328 | Somatic mutations in MAP3K5 attenuate its proapoptotic function in melanoma through increased binding to thioredoxin |
| Q55423983 | Specific increase in T cell potency via structure-based design of a T cell receptor for adoptive immunotherapy. |
| Q34383054 | Specific increase in potency via structure-based design of a TCR. |
| Q42619352 | Specific release of cytokines by lymphocytes infiltrating human melanomas in response to shared melanoma antigens. |
| Q67987672 | Specific release of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-alpha, and IFN-gamma by human tumor-infiltrating lymphocytes after autologous tumor stimulation |
| Q37043492 | Stable, Nonviral Expression of Mutated Tumor Neoantigen-specific T-cell Receptors Using the Sleeping Beauty Transposon/Transposase System. |
| Q53809960 | Staging laparotomies in unselected previously untreated patients with non-Hodgkin's lymphomas |
| Q69594250 | Staging laparotomy and splenectomy in Hodgkin's disease: analysis of indications and patterns of involvement in 285 consecutive, unselected patients |
| Q40864307 | Status of activation of circulating vaccine-elicited CD8+ T cells |
| Q104281851 | Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer |
| Q40649080 | Stimulation of tumor-reactive T lymphocytes using mixtures of synthetic peptides derived from tumor-associated antigens with diverse MHC binding affinities |
| Q27680213 | Structure-based design of altered MHC class II-restricted peptide ligands with heterogeneous immunogenicity |
| Q44849269 | Studies of effects of recombinant human tumor necrosis factor on autochthonous tumor and transplanted normal tissue in mice. |
| Q69727000 | Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo |
| Q45893718 | Study and characterization of mutated antigen specific T cells isolated from fresh tumor and peripheral lymphocytes in cancer patients |
| Q42933679 | Successful treatment of melanoma brain metastases with adoptive cell therapy. |
| Q71596799 | Surgical Staging of Abdominal Involvement in Unselected Patients with Hodgkin's Disease |
| Q34954990 | Surgical management of melanoma brain metastases in patients treated with immunotherapy. |
| Q36327111 | Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression |
| Q54254954 | Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid alpha-interferon in the treatment of established murine hepatic metastases. |
| Q68094889 | Synergistic antitumor effects of immunotherapy with recombinant interleukin-2 and recombinant tumor necrosis factor-alpha |
| Q40824218 | Systemic administration of interleukin-2 in humans |
| Q70228761 | Systemic administration of recombinant human interleukin-2 in mice |
| Q48466552 | Systemic administration of recombinant interleukin 2 stimulates in vivo lymphoid cell proliferation in tissues |
| Q69376234 | Systemic induction of cells mediating antibody-dependent cellular cytotoxicity following administration of interleukin 2 |
| Q46576941 | T cell receptor affinity and avidity defines antitumor response and autoimmunity in T cell immunotherapy |
| Q69381218 | T cell responses to Mls determinants are restricted by cross-reactive MHC determinants |
| Q33202641 | T cells associated with tumor regression recognize frameshifted products of the CDKN2A tumor suppressor gene locus and a mutated HLA class I gene product |
| Q40186710 | T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial |
| Q34621730 | T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. |
| Q92592749 | T-Cell Receptor Gene Therapy for Human Papillomavirus-Associated Epithelial Cancers: A First-in-Human, Phase I/II Study |
| Q30832820 | T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. |
| Q88938409 | T-cell Responses to TP53 "Hotspot" Mutations and Unique Neoantigens Expressed by Human Ovarian Cancers |
| Q36799229 | T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy |
| Q36449599 | T-cell receptor gene therapy of established tumors in a murine melanoma model |
| Q41452804 | T-cell receptor repertoire in tumor-infiltrating lymphocytes. Analysis of melanoma-specific long-term lines |
| Q42848657 | T-cell therapy against cancer mutations |
| Q36924688 | TGF-beta 1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells |
| Q36057454 | TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients. |
| Q36154471 | Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6 |
| Q68451405 | Technical aspects of lymphokine-activated killer cell production |
| Q45892658 | Tetramer based approach for efficient identification and isolation of neo-antigen specific CD8 T cells from peripheral blood (PBL) of patients with metastatic cancers |
| Q33577629 | The GYMSSA trial: a prospective randomized trial comparing gastrectomy, metastasectomy plus systemic therapy versus systemic therapy alone |
| Q43445412 | The Persistence of Human Peripheral Lymphocytes, Tumor Infiltrating Lymphocytes, and Colon Adenocarcinomas in Immunodeficient Mice |
| Q36923906 | The Waardenburg syndrome type 4 gene, SOX10, is a novel tumor-associated antigen identified in a patient with a dramatic response to immunotherapy |
| Q69892964 | The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo |
| Q69880385 | The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells |
| Q69934702 | The concept, evolution and preliminary results of the current Stanford clinical trials for Hodgkin's disease |
| Q41279485 | The current status and future applications of interleukin 2- and adoptive immunotherapy in cancer treatment |
| Q45873266 | The development of gene therapy for the treatment of cancer |
| Q69490209 | The effect of various cytokines on the in vitro induction of antibody-dependent cellular cytotoxicity in murine cells. Enhancement of IL-2-induced antibody-dependent cellular cytotoxicity activity by IL-1 and tumor necrosis factor-alpha |
| Q45242251 | The evolution and summary results of the Stanford randomized clinical trials of the management of Hodgkin's disease: 1962-1984. |
| Q70984165 | The fate of interleukin-2 after in vivo administration |
| Q33490318 | The hematologic toxicity of interleukin-2 in patients with metastatic melanoma and renal cell carcinoma |
| Q72079058 | The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): implications for the adoptive immunotherapy of tumors |
| Q36867815 | The intronic region of an incompletely spliced gp100 gene transcript encodes an epitope recognized by melanoma-reactive tumor-infiltrating lymphocytes |
| Q70281536 | The management of stage I--II Hodgkin's disease with irradiation alone or combined modality therapy: the Stanford experience |
| Q70817025 | The natural history of initially untreated low-grade non-Hodgkin's lymphomas |
| Q43430836 | The potential benefits of therapeutic splenectomy for patients with Hodgkin's disease and non-Hodgkin's lymphomas |
| Q33987699 | The shedding of CD62L (L-selectin) regulates the acquisition of lytic activity in human tumor reactive T lymphocytes |
| Q50940546 | The stoichiometric production of IL-2 and IFN-γ mRNA defines memory T cells that can self-renew after adoptive transfer in humans. |
| Q71002948 | The systemic administration of purified interleukin 2 enhances the ability of sensitized murine lymphocytes to cure a disseminated syngeneic lymphoma |
| Q33486169 | The treatment of advanced stage favorable histology non-Hodgkin's lymphoma: a preliminary report of a randomized trial comparing single agent chemotherapy, combination chemotherapy, and whole body irradiation. |
| Q71009949 | The treatment of malignant histiocytosis |
| Q72313142 | The use of interleukin-6 to generate tumor-infiltrating lymphocytes with enhanced in vivo antitumor activity |
| Q47807208 | The use of melanosomal proteins in the immunotherapy of melanoma |
| Q36291063 | The value of sequential bone marrow biopsy and laparotomy and splenectomy in a series of 127 consecutive untreated patients with non-Hodgkin's lymphoma |
| Q44784874 | Third-line chemotherapy for resistant Hodgkin's disease with lomustine, etoposide, and methotrexate. |
| Q37768258 | Thoracic metastasectomy for adoptive immunotherapy of melanoma: a single-institution experience |
| Q33413012 | Thrombotic microangiopathy in metastatic melanoma patients treated with adoptive cell therapy and total body irradiation |
| Q71189347 | Thyroid dysfunction in 281 patients with metastatic melanoma or renal carcinoma treated with interleukin-2 alone |
| Q36253608 | Toll-like receptors in tumor immunotherapy |
| Q45754160 | Toward cell transfer immunotherapy against patient-specific mutations in gastrointestinal cancers |
| Q69872338 | Toxicity of recombinant human interleukin-2 in rats following intravenous infusion |
| Q34795354 | Transduction of an HLA-DP4-restricted NY-ESO-1-specific TCR into primary human CD4+ lymphocytes |
| Q34669675 | Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions |
| Q36908563 | Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy |
| Q35353365 | Treating cancer with genetically engineered T cells |
| Q45870820 | Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3. |
| Q39487510 | Treatment of advanced Hodgkin's disease with B-CAVE following MOPP failure |
| Q39490709 | Treatment of advanced Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide (ABVD) after failure of MOPP therapy |
| Q67478803 | Treatment of advanced non-Hodgkin's lymphomas with favorable histologies: preliminary results of a prospective trial |
| Q37129949 | Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines |
| Q33440852 | Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study |
| Q69017552 | Treatment of refractory non-Hodgkin's lymphomas of unfavorable histology with teniposide, cytarabine, and cisplatin |
| Q33503368 | Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer |
| Q39655893 | Tumor Infiltrating Lymphocyte Therapy for Metastatic Melanoma: Analysis of Tumors Resected for TIL |
| Q34080914 | Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired |
| Q45287769 | Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma |
| Q36371632 | Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. |
| Q34657668 | Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study |
| Q39647119 | Tumor- and Neoantigen-Reactive T-cell Receptors Can Be Identified Based on Their Frequency in Fresh Tumor |
| Q91009823 | Tumor-infiltrating human CD4+ regulatory T cells display a distinct TCR repertoire and exhibit tumor and neoantigen reactivity |
| Q72884570 | Tumor-infiltrating lymphocytes derived from select B-cell lymphomas secrete granulocyte-macrophage colony-stimulating factor and tumor necrosis factor-alpha in response to autologous tumor stimulation |
| Q73373378 | Tumor-infiltrating lymphocytes from human ovarian cancer patients recognize autologous tumor in an MHC class II-restricted fashion |
| Q35613148 | Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma |
| Q37590119 | Tumor-reactive CD8+ T cells in metastatic gastrointestinal cancer refractory to chemotherapy. |
| Q84107453 | Tumor-specific CD4+ melanoma tumor-infiltrating lymphocytes |
| Q34109953 | Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts |
| Q69738303 | Tumor-specific cytolysis by lymphocytes infiltrating human melanomas |
| Q40898515 | Tumorigenicity and immunogenicity of murine tumor cells expressing an MHC class II molecule with a covalently bound antigenic peptide |
| Q92523541 | Unique Neoantigens Arise from Somatic Mutations in Patients with Gastrointestinal Cancers |
| Q43695332 | Unique murine tumor-associated antigens identified by tumor infiltrating lymphocytes |
| Q45892768 | Unique neoantigens expressed by melanomas and common epithelial cancers presented by multiple HLA alleles can be efficiently identified utilizing peptide prediction algorithms |
| Q45871736 | Upregulation of tumor necrosis factor-alpha production by retrovirally transduced human tumor-infiltrating lymphocytes using trans-retinoic acid |
| Q45892880 | Use of CD137 up-regulation to identify T cell receptors specifically reactive with mutated tumor associated antigens from tumor infiltrating lymphocytes |
| Q36905613 | Use of HLA peptidomics and whole exome sequencing to identify human immunogenic neo-antigens. |
| Q71608052 | Use of interleukin-7, interleukin-2, and interferon-gamma to propagate CD4+ T cells in culture with maintained antigen specificity |
| Q43702722 | Use of recombinant poxviruses to stimulate anti-melanoma T cell reactivity |
| Q44712586 | Use of soluble recombinant TNF receptor to improve detection of TNF secretion in cultures of tumor infiltrating lymphocytes |
| Q34703600 | Use of standard criteria for assessment of cancer vaccines. |
| Q34082215 | Use of the piggyBac transposon to create stable packaging cell lines for the production of clinical-grade self-inactivating γ-retroviral vectors |
| Q68100559 | Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report |
| Q36365832 | Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen |
| Q71659964 | Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy |
| Q37104104 | Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma |
| Q34188859 | gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma |
| Q100443984 | mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer |
| Q1324940 | Keio Medical Science Prize | winner | P1346 |
| Q63865665 | Steven A. Rosenberg | different from | P1889 |
| Arabic (ar / Q13955) | ستيفن روزنبرغ | wikipedia |
| Egyptian Arabic (arz / Q29919) | ستيفن روزنبرج | wikipedia |
| Steven A. Rosenberg | wikipedia | |
| Steven Rosenberg | wikipedia | |
| Persian (fa / Q9168) | استیون روزنبرگ | wikipedia |
| סטיבן רוזנברג | wikipedia | |
| Steven Rosenberg | wikipedia | |
| スティーヴン・ローゼンバーグ | wikipedia | |
| Steven Rosenberg | wikipedia | |
| Розенберг, Стивен | wikipedia |
Search more.